Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer

<p>Supplementary video 2</p>

Պահպանված է:

Մատենագիտական մանրամասներ
Հիմնական հեղինակ:	Min Wei (16918572) (author)
Այլ հեղինակներ:	Xinping Huang (16918575) (author), Liming Liao (16918578) (author), Yonglu Tian (16918581) (author), Xiaofeng Zheng (16918584) (author)
Հրապարակվել է:	2025
Խորագրեր:	Cancer Cancer Biology Tumor Biology Molecular and Cellular Biology Cancer Detection and Diagnosis Therapeutic Research and Development Biochemistry Protein/protein interactions Biomarkers Protein biomarkers Carcinogenesis DNA damage and repair DNA Damage and Repair Drug Resistance Regulation of gene expression in drug resistance Gastrointestinal Cancers Colorectal cancer Oncogenes & Tumor Suppressors Oncogenes Progression, Invasion & Metastasis
Ցուցիչներ:	Ավելացրեք ցուցիչ Չկան պիտակներ, Եղեք առաջինը, ով նշում է այս գրառումը!

Նմանատիպ նյութեր

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
‌: Min Wei (16918572)
Հրապարակվել է: (2025)

Supplementary Data 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
‌: Kavya Ramkumar (16474203)
Հրապարակվել է: (2025)

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S2 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S2 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S3 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S3 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S4 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S4 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S5 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S5 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S6 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S6 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S7 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S7 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure S7 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Supplementary Tables from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
‌: Craig M. Goodwin (14955973)
Հրապարակվել է: (2025)

Figure 1 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
‌: Marta J. Llorca-Cardenosa (14961612)
Հրապարակվել է: (2025)

Figure 2 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
‌: Marta J. Llorca-Cardenosa (14961612)
Հրապարակվել է: (2025)

Figure 3 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
‌: Marta J. Llorca-Cardenosa (14961612)
Հրապարակվել է: (2025)

Figure 4 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
‌: Marta J. Llorca-Cardenosa (14961612)
Հրապարակվել է: (2025)

Figure 5 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
‌: Marta J. Llorca-Cardenosa (14961612)
Հրապարակվել է: (2025)

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
‌: Sanna Pikkusaari (15055802)
Հրապարակվել է: (2025)

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
‌: Sanna Pikkusaari (15055802)
Հրապարակվել է: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
‌: Long Jiang (14956159)
Հրապարակվել է: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
‌: Long Jiang (14956159)
Հրապարակվել է: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
‌: Long Jiang (14956159)
Հրապարակվել է: (2025)

Figure 1 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
‌: Katrina M. Lappin (9340394)
Հրապարակվել է: (2025)

Figure 2 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
‌: Katrina M. Lappin (9340394)
Հրապարակվել է: (2025)

Figure 3 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
‌: Katrina M. Lappin (9340394)
Հրապարակվել է: (2025)

Figure 4 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
‌: Katrina M. Lappin (9340394)
Հրապարակվել է: (2025)

Supplementary Tables S1-S11 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects
‌: Sami Belhadj (15052341)
Հրապարակվել է: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
‌: Arun Kanakkanthara (14937731)
Հրապարակվել է: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
‌: Arun Kanakkanthara (14937731)
Հրապարակվել է: (2025)

Cannot write session to /tmp/vufind_sessions/sess_4d1n06gajto0uvbgmfeveu75n8